Establishing a High-quality Biomedical Resource for Rare Diseases：<?A3B2 pi6?>Insights from Pediatric Medulloblastoma

Rare cancers，despite their low individual incidence，encompass a wide array of subtypes and collectively account for more than 20% of all malignancies. Progress in this field has been constrained by limited sample availability and fragmented research resources，making precision diagnosis and targeted therapy heavily reliant on high-quality，openly accessible databases. While recent advances in genomic technologies have facilitated progress in selecting rare cancer types，the persistence of data silos and insufficient data integration remains a critical barrier to the development of precision oncology. Taking pediatric medulloblastoma as the insight，we examine the current state of biomedical data infrastructure for rare cancers，assess the impact of data fragmentation on research productivity，and outline strategic recommendations for building robust，high-resolution databases to accelerate discovery and improve patient outcomes.